Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)

The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergic Rhinitis Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Nose Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis, Allergic

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis.

Exclusion criteria

Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection [symptoms may exacerbate]
Patients with a history of hypersensitivity to any ingredient of this drug

Treatment and study plan

Mometasone furoate

Drug

Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)

Duration: up to 6 months

Other names: Nasonex® Nasal Suspension, Nasonex

Primary outcomes

Estimate the incidence of Adverse Drug Reactions (ADRs)

Time frame: After 6 months of observation

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation

Important dates

Study start: 2008
Primary completion: 2012
Study completion: 2012
First posted: May 18, 2009
Registry last updated: Feb 16, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed